Day: November 9, 2023

Seneca Foods Reports Sales and Earnings for the Quarter and Six Months Ended September 30, 2023

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

FAIRPORT, N.Y., Nov. 09, 2023 (GLOBE NEWSWIRE) — Seneca Foods Corporation (NASDAQ: SENEA, SENEB) today announced financial results for the second quarter and six months ended September 30, 2023. Executive Summary (vs. year-ago, year-to-date results): Net sales for the six months ended September 30, 2023 totaled $706.1 million compared to $705.0 for the six months ended October 1, 2022. The year-over-year increase of $1.1 million was mainly due to higher selling prices partially offset by lower sales volumes. Gross margin as a percentage of net sales for the six months ended September 30, 2023 is 16.1% as compared to 9.2% for the six months ended October 1, 2022. “The Company continued its strong performance through the first half of fiscal 2024 with net sales and FIFO EBITDA exceeding fiscal 2023 results for the same period....

Continue reading

Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

–  Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics –  Proprietary cell-targeted LNP delivery system showed highly selective T cell transduction in humanized mouse model, demonstrating in vivo targeting for T cells and potentially for other extrahepatic tissues and cell types –  Third quarter 2023 cash balance of $291.0 million expected to fund operations into 2026 CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2023 financial results. “The recent advances in our immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP)...

Continue reading

Montauk Renewables Announces Third Quarter 2023 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

PITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery, and conversion of biogas into renewable natural gas (“RNG”), today announced financial results for the third quarter ended September 30, 2023. Third Quarter Financial Highlights: Revenues of $55.7 million, decreased 0.3% as compared to the third quarter of 2022 Net Income of $12.9 million, increased 15.6% as compared to the third quarter of 2022 Non-GAAP Adjusted EBITDA of $22.4 million, increased 7.4% as compared to the third quarter of 2022 RNG production of 1.4 million MMBtu, decreased 4.0% as compared to the third quarter of 2022 In the third quarter of 2023, our Board of Directors approved funding for the first phase of the North Carolina...

Continue reading

Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

WARRINGTON, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2023 and provided key business updates. “During the third quarter, we initiated our plan to move the istaroxime program in cardiogenic shock to Phase 3 readiness by advancing two clinical trials. First, we began building upon the positive data from the SEISMiC study by progressing the SEISMiC Extension Study for dose optimization in U.S., Europe and Latin American countries and sites. Additionally, we continued to progress start-up activities for a study of istaroxime in more severe SCAI Stage C cardiogenic shock patients that, with...

Continue reading

Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Topline Results from Phase 3 Potentially NDA-Enabling Study of TNX-102 SL in Fibromyalgia Expected Late December 2023: Centrally-Acting Non-Opioid Analgesic Topline Results from Phase 2 Proof-of-Concept Study of TNX-1900 in Chronic Migraine Expected Early December 2023: Intranasal Potentiated Oxytocin Meaningful Progress Made in Obtaining External Support for Clinical Trials from U.S. Government Agencies and Other Institutions Revenue from Marketed Acute Migraine Products: Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) Included in Third Quarter Financial Statements CHATHAM, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced...

Continue reading

Pineapple Energy Reports Third Quarter 2023 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Revenue up 211% from Q3 2022 Gross profit up 401% from Q3 2022 Operating Expenses up 125% from Q3 2022 Net Loss from continuing operations decreased 8% from Q3 2022 Pro forma adjusted EBITDA up 156% from Q3 2022 Positive cash flow from operations of $869,851 MINNETONKA, Minn., Nov. 09, 2023 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (NASDAQ: PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced financial results for the third quarter ended September 30, 2023. Pineapple CEO Kyle Udseth commented, “My main message is quite similar to three months ago. We were able to deliver a strong third quarter, which is a nice counter to the reports of underperformance from some of our larger public peers who have already reported. The residential solar industry does continue...

Continue reading

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data analysis completion expected before year-end. PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited financial and operating results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Results Total revenue for Q3 2023, including product sales and grant income, was $8.8 million, an increase of 9% compared to $8.1 million in Q3 2022 Q3 2023 product sales were $7.8 million versus...

Continue reading

HF Foods Reports Third Quarter 2023 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Pre-Recorded Earnings Call Webcast Available on Investor Relations Website Announces Comprehensive, Operational Transformation Plan to Drive Growth and Cost Savings LAS VEGAS, Nov. 09, 2023 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods”, or the “Company”), a leading food distributor to Asian restaurants across the United States, reported financial results for the third quarter and nine months ended September 30, 2023. Third Quarter 2023 Financial Results Net revenue decreased 6.4% to $281.5 million compared to $300.7 million in the prior year. Gross profit decreased 1.1% to $50.9 million, or 18.1% gross profit margin compared to $51.5 million, or 17.1% gross profit margin in the prior year. Net income (loss) increased to net income of $2.0 million compared to net loss of $3.9 million in the prior year. Adjusted...

Continue reading

Sienna Senior Living Inc. Reports Strong Third Quarter 2023 Financial Results and Delivers Fourth Consecutive Quarter of AFFO Growth per Share

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

MARKHAM, Ontario, Nov. 09, 2023 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced its financial results for the three and nine months ended September 30, 2023. The Consolidated Financial Statements and accompanying Management’s Discussion and Analysis (“MD&A”) are available on the Company’s website at www.siennaliving.ca and on SEDAR at www.sedar.com. Sienna’s strong year over year growth in the third quarter, which marks the Company’s fourth consecutive quarter of improvements in Adjusted Funds from Operations (“AFFO”) per share, underscores our continued focus on operating efficiencies, enhancing team member engagement and the successful reduction of agency staffing to pre-pandemic levels, and resulted in net operating income (“NOI”) growth and a double digit increase in...

Continue reading

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Completed dose escalation in Phase 1 Trial of INB-100 with updated clinical data to be presented at the American Society of Hematology (ASH) Annual Meeting on December 11, 2023 (Abstract Number: 4853). Held Research & Development Day, featuring Leo Luznik, M.D. from Johns Hopkins University and Michael Bishop, M.D. from The University of Chicago, highlighting IN8bio’s differentiated clinical and scientific programs and multiple upcoming clinical catalysts. Presented positive updated biologic correlative data on INB-200 in glioblastoma (GBM) and preclinical data on INB-500 featuring induced pluripotent stem cell (iPSC) derived gamma-delta T cells at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. Initiated enrollment for Phase 2 trial of INB-400 in newly diagnosed GBM (NCT05664243). Updated Phase 1 clinical data...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.